GlassScriptPhysician profile
Brianna Schmidt
NPI 1952808842
$480.83
in general payments reported to CMS, 2019-2025
15 companies · $35.13 in 2025
The $35.13 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.42 · 2022: $207 · 2023: $103 · 2024: $94.31 · 2025: $35.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $85.25 | 2023-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $81.37 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.65 | 2022 | |
| Daiichi Sankyo INC. | $46.06 | 2022-2023 | Injectafer |
| Glaxosmithkline, LLC. | $41.94 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $35.18 | 2022 | |
| Amgen INC. | $23.28 | 2022 | |
| Medtronic, INC. | $18.88 | 2022 | |
| Edwards Lifesciences Corporation | $15.62 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ardelyx, INC. | $14.52 | 2024 | Ibsrela |
| Pfizer INC. | $14.09 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.44 | 2024 | Breztri |
| Lilly USA, LLC | $13.26 | 2023 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $13.08 | 2023 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.